Endothelial NF-kappaB as a mediator of kidney damage: the missing link between systemic vascular and renal disease?
Tomasz J
TJ
Guzik
David G
DG
Harrison
D000419:Albuminuria / Q000209:etiology / Q000517:prevention & control; D000804:Angiotensin II / Q000633:toxicity; D000818:Animals; D050197:Atherosclerosis / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000378:metabolism*; D005355:Fibrosis; D015248:Gemfibrozil / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000378:metabolism; D020672:I-kappa B Proteins / Q000235:genetics / Q000502:physiology; D007249:Inflammation / Q000503:physiopathology; D007674:Kidney Diseases / Q000209:etiology* / Q000517:prevention & control; D051379:Mice; D008955:Models, Cardiovascular; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000502:physiology*; D009569:Nitric Oxide / Q000502:physiology; D052250:Nitric Oxide Synthase Type III / Q000037:antagonists & inhibitors; D009928:Organ Specificity; D017673:Sodium Chloride, Dietary / Q000633:toxicity
D020672:I-kappa B Proteins; D016328:NF-kappa B; C000606204:NFKBIA protein, human; C000606205:Nfkbia protein, mouse; D017673:Sodium Chloride, Dietary; D000804:Angiotensin II; D000072000:NF-KappaB Inhibitor alpha; D009569:Nitric Oxide; D052250:Nitric Oxide Synthase Type III; D015248:Gemfibrozil